HBM Healthcare Investments

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

Numab Therapeutics is an oncology-focused biopharmaceutical company that designs and develops antibody-based and multispecific therapeutics for cancer, inflammatory diseases, autoimmunity, and related severe conditions. It employs a plug-and-play platform that reduces the randomness of discovery and aims to predictably yield mono- or multispecific antibody fragments with tailored pharmacokinetic properties to engage multiple targets. Founded in 2011 and based in Wädenswil, Switzerland, Numab pursues immuno-oncology and inflammation programs through this multispecific approach, prioritizing therapies with improved selectivity and potential clinical efficacy.

Molecular Partners is a clinical-stage biopharmaceutical company dedicated to advancing modern medicine through the development of innovative therapies. The company specializes in a novel class of small protein therapeutics known as DARPin therapeutics, which are designed to target serious diseases, including cancer and sight-threatening disorders. Molecular Partners' product pipeline is organized into three primary areas: ophthalmology, focusing on therapies for retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, which includes DARPin candidates that feature unique mechanisms of action; and additional therapeutic areas. The firm's commitment to developing potent and versatile treatments positions it at the forefront of biopharmaceutical innovation.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

Cartesian Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene immunotherapies to treat cancer and autoimmune diseases. The company designs chimeric antigen receptor therapies for multiple myeloma and other cancers and uses its ImmTOR immune tolerance platform to mitigate antigen-specific immune responses. It operates a proprietary technology and manufacturing platform to deliver one or more mRNA molecules into cells to enhance their function, aiming to improve therapeutic performance.

Bluejay Therapeutics is a private biopharmaceutical company focused on developing curative treatments for infectious and liver diseases. Its initial program targets chronic hepatitis B, a widespread infection with unmet medical need, using two approaches: fully human IgG1 monoclonal antibodies against hepatitis B surface antigen and oral small-molecule inhibitors of HBsAg. The aim is to reduce viral surface antigen and restore adaptive immunity, potentially achieving a functional cure for HBV and enabling patients to regain immune control of infection. The company’s work also contemplates extending its approach to other viral liver diseases, including chronic hepatitis D.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Alumis is a clinical-stage biopharmaceutical company specializing in precision medicines for autoimmune disorders. It leverages its proprietary precision data analytics platform and expertise in immunology to develop targeted therapies that significantly improve patients' lives.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Upstream Bio is a clinical-stage biotechnology company focused on developing antibody therapies for severe respiratory disorders. Its lead product, Verekitug, targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in inflammatory responses.

Numab Therapeutics is an oncology-focused biopharmaceutical company that designs and develops antibody-based and multispecific therapeutics for cancer, inflammatory diseases, autoimmunity, and related severe conditions. It employs a plug-and-play platform that reduces the randomness of discovery and aims to predictably yield mono- or multispecific antibody fragments with tailored pharmacokinetic properties to engage multiple targets. Founded in 2011 and based in Wädenswil, Switzerland, Numab pursues immuno-oncology and inflammation programs through this multispecific approach, prioritizing therapies with improved selectivity and potential clinical efficacy.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Mahzi Therapeutics is a health care and biotechnology company based in San Mateo, California. Founded in 2020, it specializes in the research, development, and manufacturing of biopharmaceuticals to address underserved rare genetic neurodevelopmental disorders and related neuroregenerative diseases, developing molecular therapeutics to enable treatment options.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

Adrenomed is a privately financed, clinical-stage biopharmaceutical company focused on restoring vascular integrity in critically ill patients. Its lead candidate, Adrecizumab, is a humanized monoclonal antibody that targets Adrenomedullin, a regulator of the vascular system, to reduce vascular leakage and stabilize circulation in conditions such as sepsis and septic shock and acute heart failure. The company employs a biomarker-guided approach, pairing the antibody with Adrenomedullin measurements to identify suitable patients. Headquartered in Hennigsdorf, near Berlin, Germany, Adrenomed develops therapeutic and diagnostic strategies to treat acute circulatory failure and improve survival in high-risk conditions.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Upstream Bio is a clinical-stage biotechnology company focused on developing antibody therapies for severe respiratory disorders. Its lead product, Verekitug, targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in inflammatory responses.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

Founded in 2018, Neuron23 is a biotechnology company based in South San Francisco, California, with an additional office in Munich, Germany. It specializes in developing and manufacturing medicines for genetic disorders using artificial intelligence technology and genetics.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Adrenomed is a privately financed, clinical-stage biopharmaceutical company focused on restoring vascular integrity in critically ill patients. Its lead candidate, Adrecizumab, is a humanized monoclonal antibody that targets Adrenomedullin, a regulator of the vascular system, to reduce vascular leakage and stabilize circulation in conditions such as sepsis and septic shock and acute heart failure. The company employs a biomarker-guided approach, pairing the antibody with Adrenomedullin measurements to identify suitable patients. Headquartered in Hennigsdorf, near Berlin, Germany, Adrenomed develops therapeutic and diagnostic strategies to treat acute circulatory failure and improve survival in high-risk conditions.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

SK Biopharmaceuticals Co., Ltd., founded in 2011 and headquartered in Seongnam, South Korea, focuses on the research, discovery, and development of pharmaceuticals targeting central nervous system disorders. The company is advancing several key products, including Cenobamate for epilepsy, Solriamfetol for excessive daytime sleepiness, and Carisbamate for Lennox-Gastaut syndrome, with various candidates in different stages of clinical trials. Other investigational drugs include Relenopride for rare neurological diseases and compounds targeting attention deficit/hyperactivity disorder, schizophrenia, bipolar disorder, and epilepsy. SK Biopharmaceuticals aims to establish itself as a leading specialty pharmaceutical company by developing innovative treatments and providing high-quality pharmaceutical manufacturing services.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapeutics. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond positively to specific treatments, thereby enhancing the effectiveness of its drug development efforts. Acrivon's pipeline features its lead program, ACR-368 (prexasertib), which is currently in Phase 2 trials, alongside several preclinical programs targeting key components of DNA damage response and cell cycle regulation, including WEE1 and PKMYT1. By concentrating on complex oncology drug targets that are often not addressed by traditional therapies, Acrivon aims to expedite the advancement of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials.

Ignis Therapeutics is a life science company focused on developing innovative therapies for central nervous system (CNS) conditions. Committed to advancing treatment paradigms, the company aims to transform the approach to treating CNS disorders. Ignis Therapeutics is dedicated to creating products that significantly enhance the quality of life for patients while offering additional therapeutic options for healthcare providers. Through its emphasis on self-discovery and strategic development, Ignis Therapeutics seeks to address unmet medical needs in the CNS space.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Upstream Bio is a clinical-stage biotechnology company focused on developing antibody therapies for severe respiratory disorders. Its lead product, Verekitug, targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in inflammatory responses.

Mahzi Therapeutics is a health care and biotechnology company based in San Mateo, California. Founded in 2020, it specializes in the research, development, and manufacturing of biopharmaceuticals to address underserved rare genetic neurodevelopmental disorders and related neuroregenerative diseases, developing molecular therapeutics to enable treatment options.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its unique T-win technology platform, the company creates first-in-class immune-modulating cancer vaccines that aim to activate T cells specific to immune-suppressive molecules. This approach allows for the simultaneous targeting and disruption of multiple pathways that tumors exploit to evade the immune response. IO Biotech has demonstrated a strong capability in advancing its preclinical and clinical candidates, with its two leading compounds targeting IDO and PD-L1 currently in clinical development, while several others are in the preclinical phase.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

Numab Therapeutics is an oncology-focused biopharmaceutical company that designs and develops antibody-based and multispecific therapeutics for cancer, inflammatory diseases, autoimmunity, and related severe conditions. It employs a plug-and-play platform that reduces the randomness of discovery and aims to predictably yield mono- or multispecific antibody fragments with tailored pharmacokinetic properties to engage multiple targets. Founded in 2011 and based in Wädenswil, Switzerland, Numab pursues immuno-oncology and inflammation programs through this multispecific approach, prioritizing therapies with improved selectivity and potential clinical efficacy.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

Adrenomed is a privately financed, clinical-stage biopharmaceutical company focused on restoring vascular integrity in critically ill patients. Its lead candidate, Adrecizumab, is a humanized monoclonal antibody that targets Adrenomedullin, a regulator of the vascular system, to reduce vascular leakage and stabilize circulation in conditions such as sepsis and septic shock and acute heart failure. The company employs a biomarker-guided approach, pairing the antibody with Adrenomedullin measurements to identify suitable patients. Headquartered in Hennigsdorf, near Berlin, Germany, Adrenomed develops therapeutic and diagnostic strategies to treat acute circulatory failure and improve survival in high-risk conditions.

Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.

Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Visen Pharmaceuticals is an innovative biopharmaceutical company focused on developing and providing advanced treatments for endocrine diseases in China. With a patient-centric approach, Visen aims to deliver first-in-class or best-in-class products, covering both common and rare endocrine conditions in adults and children. The company leverages cutting-edge technologies and global resources, with established offices in Shanghai, Beijing, Hong Kong, and Taipei, along with a Greater China R&D and manufacturing site in Suzhou.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative receptor agonists for cancer immunotherapy. Founded in 2017, the company is dedicated to creating therapeutics that stimulate the body’s immune system to combat cancer. Utilizing its proprietary PREDATOR platform, Werewolf designs conditionally activated molecules known as INDUKINE, which are engineered to remain inactive in peripheral tissues while selectively activating within the tumor microenvironment. This approach aims to overcome the limitations of traditional proinflammatory immune therapies, enhancing both adaptive and innate immunity to improve cancer treatment outcomes.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Instil Bio develops and commercializes tumor infiltrating lymphocyte (TIL) therapies for treating various cancers. Founded in 2018, the company harvests patients' T cells from tumors, expands them, and reinfuses them to target cancer cells.

Founded in 2018, Neuron23 is a biotechnology company based in South San Francisco, California, with an additional office in Munich, Germany. It specializes in developing and manufacturing medicines for genetic disorders using artificial intelligence technology and genetics.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.

Adrenomed is a privately financed, clinical-stage biopharmaceutical company focused on restoring vascular integrity in critically ill patients. Its lead candidate, Adrecizumab, is a humanized monoclonal antibody that targets Adrenomedullin, a regulator of the vascular system, to reduce vascular leakage and stabilize circulation in conditions such as sepsis and septic shock and acute heart failure. The company employs a biomarker-guided approach, pairing the antibody with Adrenomedullin measurements to identify suitable patients. Headquartered in Hennigsdorf, near Berlin, Germany, Adrenomed develops therapeutic and diagnostic strategies to treat acute circulatory failure and improve survival in high-risk conditions.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the development of engineered precision biologics through an expanded genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, facilitating the creation of next-generation therapeutics. Ambrx focuses on various product candidates, including antibody drug conjugates (ADCs), bispecific antibodies, targeted immuno-oncology treatments, and long-acting therapeutic peptides aimed at addressing metabolic and cardiovascular diseases. The company has a robust development pipeline featuring multiple clinical and preclinical programs, with its lead candidate ARX788 among them. Ambrx also collaborates with other organizations, such as MabSpace Biosciences and BeiGene, to enhance its research and development efforts in oncology and other therapeutic areas. Founded in 2003, Ambrx is committed to advancing the efficacy and safety of new biologic therapies for patients.

Longboard Pharmaceuticals, Inc., established in 2020 and headquartered in San Diego, California, is engaged in developing optimized medicines targeting neurological diseases. The company focuses on improving pharmacology and pharmacokinetics to create novel treatments for rare conditions. Its pipeline includes LP352, a next-generation 5-HT2C agonist being evaluated for developmental and epileptic encephalopathies; LP143, a centrally acting CB2 receptor full agonist explored for potential treatment of neurological disorders like ALS and PD; and LP659, a highly selective S1P receptor modulator targeting multiple CNS neuroinflammatory disorders. Longboard operates as a subsidiary of Arena Pharmaceuticals, Inc., aiming to deliver these medicines to patients in need.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

BioShin Limited is a clinical-stage biopharmaceutical company focused on developing innovative medicines for neurological, neuropsychiatric diseases, and rare disorders. Established in 2018 and based in Pudong, China, BioShin operates as a wholly owned subsidiary of Biohaven Pharmaceutical Holding Company Ltd. The company is engaged in developing late-stage product candidates and offers clinical trial platforms that explore various therapeutic approaches, including calcitonin gene-related peptide receptor antagonism for migraine relief, glutamate modulation for Alzheimer’s disease and anxiety disorders, and myeloperoxidase inhibition targeting inflammation and neurodegeneration. By addressing significant unmet medical needs in neurological care, BioShin aims to make a substantial impact in the Asia-Pacific market.

Galecto is a clinical-stage biotechnology company developing small molecule therapeutics targeting galectin-3 and lysyl oxidase-like 2 for treating severe diseases like fibrosis and cancer. Its lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 for treating severe fibrotic lung diseases such as idiopathic pulmonary fibrosis.

Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

Seer, Inc. is a life sciences company that specializes in nanoparticle technology solutions aimed at advancing proteomics research. The company offers Proteograph, an integrated system that includes consumables, automation instrumentation, and proprietary software for conducting proteomics analysis. Seer's products are designed for research applications, targeting academic institutions, life sciences laboratories, and biopharmaceutical companies for non-diagnostic and non-clinical uses. Additionally, Seer is focused on developing a health data platform that enhances early detection of chronic diseases by capturing and translating molecular insights from the proteome, thereby enabling healthcare professionals to identify conditions such as cancer and neurological disorders more accurately and rapidly. Founded in 2017 and headquartered in Redwood City, California, Seer was previously known as Seer Biosciences, Inc. before rebranding in July 2018.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Adrenomed is a privately financed, clinical-stage biopharmaceutical company focused on restoring vascular integrity in critically ill patients. Its lead candidate, Adrecizumab, is a humanized monoclonal antibody that targets Adrenomedullin, a regulator of the vascular system, to reduce vascular leakage and stabilize circulation in conditions such as sepsis and septic shock and acute heart failure. The company employs a biomarker-guided approach, pairing the antibody with Adrenomedullin measurements to identify suitable patients. Headquartered in Hennigsdorf, near Berlin, Germany, Adrenomed develops therapeutic and diagnostic strategies to treat acute circulatory failure and improve survival in high-risk conditions.

Everest Medicines is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for critical unmet medical needs, initially focusing on Asia Pacific markets.

Adrenomed is a privately financed, clinical-stage biopharmaceutical company focused on restoring vascular integrity in critically ill patients. Its lead candidate, Adrecizumab, is a humanized monoclonal antibody that targets Adrenomedullin, a regulator of the vascular system, to reduce vascular leakage and stabilize circulation in conditions such as sepsis and septic shock and acute heart failure. The company employs a biomarker-guided approach, pairing the antibody with Adrenomedullin measurements to identify suitable patients. Headquartered in Hennigsdorf, near Berlin, Germany, Adrenomed develops therapeutic and diagnostic strategies to treat acute circulatory failure and improve survival in high-risk conditions.

Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.

iTeos Therapeutics is a biotechnology company focused on immuno-oncology, developing cancer therapies that target the tumor microenvironment to overcome immune suppression and enhance efficacy of existing treatments. The company pursues small molecule and antibody approaches, including EOS-850, a small molecule antagonist of the adenosine A2A receptor, and EOS-448, an antagonist of TIGIT, with early-stage clinical programs designed to restore immune activity against tumors. By modulating metabolic and immune pathways within the tumor microenvironment, iTeos aims to improve responses across cancer types and complement immune checkpoint therapies.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.

Harmony Biosciences Holdings is a commercial-stage pharmaceutical company based in Plymouth Meeting, Pennsylvania, founded in 2017. It develops and commercializes therapies for rare neurological disorders with unmet medical needs. Its lead product is WAKIX (pitolisant), used to treat narcolepsy, and the company maintains a pipeline that includes candidates such as HBS-102, BP1.15205, ZYN002, EPX-100 and EPX-200.

MicroOptx, Inc. is a medical device company based in Maple Grove, Minnesota, specializing in innovative solutions for glaucoma treatment. Founded in 2014, the company develops advanced medical devices including the Beacon Aqueous Microshunt (BAM), designed to shunt aqueous humor from the anterior chamber to the surface of the eye, thereby reducing intraocular pressure. Additionally, MicroOptx produces SalVO, a minimally invasive glaucoma surgery micro implant intended for use in animals. The company combines expertise in bioengineering, surgical techniques, microengineering, and nanotechnology to address the challenges posed by glaucoma, a progressive disease that can lead to blindness. With a commitment to improving patient outcomes, MicroOptx aims to revolutionize the treatment landscape for glaucoma.

Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on the research and development of innovative treatments for severe inflammation and autoimmune diseases. The company's lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, which is expressed on various immune system B cells. This candidate is being developed for multiple indications, including neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. Additionally, Viela Bio is advancing VIB4920, aimed at preventing kidney transplant rejection and treating sjögren’s syndrome, as well as VIB7734, which targets cutaneous lupus erythematosus. The company has established a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several Asian markets. Founded in 2017, Viela Bio aims to address critical pathways underlying these diseases and improve patient outcomes globally.

Cathay Biotech is a prominent player in the field of synthetic biology, specializing in the production of bio-based materials derived from renewable sources. The company is recognized for its innovative approach, which enables the commercial production of long-chain dibasic acids and pentamethylene diamine, both essential monomers for manufacturing polyamides used in engineering and textiles. By employing environmentally friendly and economically viable bio-production processes, Cathay aims to replace traditional chemical manufacturing methods, thereby addressing environmental concerns and enhancing worker safety. The company operates two production facilities in China and conducts its research and development activities at its headquarters in the Zhangjiang Hi-Tech Park in Shanghai. With a commitment to sustainability, Cathay Biotech is positioned as a leader in the transition towards greener materials in the global market.

Arrakis Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, that specializes in drug discovery focused on ribonucleic acid (RNA) targets. Established in 2015, the company utilizes a proprietary platform that combines advanced RNA bioinformatics, structural tools, and chemical libraries to identify new RNA targets and develop RNA-targeted small molecules (rSMs). This innovative approach aims to address various diseases, including cancer, neurological disorders, and rare genetic conditions. Arrakis also offers SHAPEware, a software tool designed to analyze and predict RNA secondary structures and potential ligand-binding sites, further enhancing its drug development capabilities. Through its comprehensive pipeline, Arrakis Therapeutics seeks to improve treatment options and outcomes for patients across multiple therapeutic areas.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.

SAI Life Sciences is a global pharmaceutical services provider offering integrated solutions across drug discovery, development, and manufacturing for clients worldwide. Established in 1999, the company specializes in discovering, developing, and manufacturing medicines, with a focus on small molecule new chemical entities (NCEs). SAI operates through multiple facilities in India, Japan, the United States, and Europe, offering services such as synthetic chemistry, medicinal chemistry, biology, pharmacology, toxicology, and late-phase manufacturing. Its mission is to enable partners to develop innovative medicines more efficiently by providing reliable, high-quality scientific solutions.

Adrenomed is a privately financed, clinical-stage biopharmaceutical company focused on restoring vascular integrity in critically ill patients. Its lead candidate, Adrecizumab, is a humanized monoclonal antibody that targets Adrenomedullin, a regulator of the vascular system, to reduce vascular leakage and stabilize circulation in conditions such as sepsis and septic shock and acute heart failure. The company employs a biomarker-guided approach, pairing the antibody with Adrenomedullin measurements to identify suitable patients. Headquartered in Hennigsdorf, near Berlin, Germany, Adrenomed develops therapeutic and diagnostic strategies to treat acute circulatory failure and improve survival in high-risk conditions.

Galecto is a clinical-stage biotechnology company developing small molecule therapeutics targeting galectin-3 and lysyl oxidase-like 2 for treating severe diseases like fibrosis and cancer. Its lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 for treating severe fibrotic lung diseases such as idiopathic pulmonary fibrosis.

Turning Point Therapeutics is a clinical-stage biopharmaceutical company focused on designing and developing novel small molecule targeted oncology therapies. Its pipeline includes repotrectinib, TPX-0046, TPX-0022, and preclinical ALK inhibitor TPX-0131, targeting genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

Aptinyx Inc. is a clinical-stage biopharmaceutical company based in Evanston, Illinois, that specializes in discovering and developing innovative therapies for disorders of the brain and nervous system. Founded in 2015, the company focuses on proprietary synthetic small molecules that modulate the NMDA receptor, enhancing nerve cell communication. Aptinyx's pipeline includes NYX-2925, which is in Phase II clinical development for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, NYX-458, another NMDA receptor modulator, is undergoing Phase I studies aimed at treating cognitive impairment associated with Parkinson's disease. The company also collaborates with Allergan plc to develop a compound for major depressive disorder, highlighting its commitment to addressing significant unmet medical needs in the central nervous system arena.

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative antibody-based therapies for cancer treatment in the United States. The company's lead product, DANYELZA, is an FDA-approved monoclonal antibody targeting ganglioside GD2, which is present in various neuroectoderm-derived tumors and sarcomas. Y-mAbs is advancing several other candidates, including naxitamab, currently in Phase 2 trials for pediatric patients with relapsed osteosarcoma and high-risk neuroblastoma, and omburtamab, also in Phase 2 trials for desmoplastic small round cell tumors. Additionally, the company is developing a GD2-GD3 vaccine and exploring the huB7-H3 candidate for adult solid tumors. Y-mAbs collaborates with leading institutions, including Memorial Sloan Kettering Cancer Center and the Massachusetts Institute of Technology, to enhance its antibody constructs using advanced therapeutic platforms. Founded in 2015 and headquartered in New York, Y-mAbs aims to provide novel treatments that may reduce the long-term toxicities associated with traditional chemotherapies while potentially offering curative options for patients with widespread disease.

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative antibody-based therapies for cancer treatment in the United States. The company's lead product, DANYELZA, is an FDA-approved monoclonal antibody targeting ganglioside GD2, which is present in various neuroectoderm-derived tumors and sarcomas. Y-mAbs is advancing several other candidates, including naxitamab, currently in Phase 2 trials for pediatric patients with relapsed osteosarcoma and high-risk neuroblastoma, and omburtamab, also in Phase 2 trials for desmoplastic small round cell tumors. Additionally, the company is developing a GD2-GD3 vaccine and exploring the huB7-H3 candidate for adult solid tumors. Y-mAbs collaborates with leading institutions, including Memorial Sloan Kettering Cancer Center and the Massachusetts Institute of Technology, to enhance its antibody constructs using advanced therapeutic platforms. Founded in 2015 and headquartered in New York, Y-mAbs aims to provide novel treatments that may reduce the long-term toxicities associated with traditional chemotherapies while potentially offering curative options for patients with widespread disease.

BaseHealth, Inc. is a health management company that offers a predictive health platform designed to assist physicians and their patients in assessing disease risks. Founded in 2008 and based in Redwood City, California, the platform integrates genomic, medical, behavioral, and environmental data to provide personalized insights and action plans for preventing various diseases. By leveraging machine learning, the platform analyzes extensive medical literature and patient records, enabling healthcare providers to identify patients at risk for 43 chronic diseases, thereby facilitating proactive health management. Additionally, BaseHealth's platform functions as a clinical support tool, enhancing decision-making through expert knowledge and health analytics, while offering tailored recommendations on diet and physical activity based on individual health conditions and genetic profiles. As of March 2020, BaseHealth operates as a subsidiary of Genalyte, Inc.

Harmony Biosciences Holdings is a commercial-stage pharmaceutical company based in Plymouth Meeting, Pennsylvania, founded in 2017. It develops and commercializes therapies for rare neurological disorders with unmet medical needs. Its lead product is WAKIX (pitolisant), used to treat narcolepsy, and the company maintains a pipeline that includes candidates such as HBS-102, BP1.15205, ZYN002, EPX-100 and EPX-200.

ARMO BioSciences is a biotechnology company based in Redwood City, California, focused on developing immune modulatory biologic therapeutics. The company specializes in immuno-oncology, aiming to activate the immune system of cancer patients to recognize and eradicate tumors. Its pipeline includes several product candidates: AM0010, a long-acting form of interleukin 10 (IL-10) that stimulates the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). The company was incorporated in 2010 and formerly known as Targenics.

Homology Medicines is a biotechnology company focused on developing genetic therapies for rare diseases. Its proprietary platform uses human hematopoietic stem cell-derived adeno-associated virus vectors to deliver treatments in vivo, targeting various tissues including the liver and central nervous system. The company's lead product candidate, HMI-102, is in clinical trials for treating phenylketonuria.

Complexa, Inc. is a biopharmaceutical company focused on developing innovative medicines for severe and life-threatening conditions related to fibrosis and inflammation. Founded in 2008 and based in Berwyn, Pennsylvania, the company specializes in researching endogenous human cell signaling technologies to address a range of inflammatory, fibrotic, and central nervous system diseases. Its proprietary technology centers on the synthesis and therapeutic use of endogenous nitro-fatty acids, which serve as cell-signaling agents that modulate key inflammatory pathways. Notable among its developments is CXA-10, an oral nitrated fatty acid compound aimed at treating conditions such as focal segmental glomerulosclerosis and pulmonary arterial hypertension. Through its research efforts, Complexa aims to enhance existing anti-inflammatory and metabolic signaling mechanisms to support the resolution and repair of both acute and chronic tissue injuries.

Forbius, also known as Formation Biologics, is a clinical-stage biopharmaceutical company focused on designing and developing innovative therapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, the company specializes in creating agents that target critical biological pathways, specifically the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. By leveraging advanced protein engineering technologies and a deep understanding of biology, Forbius aims to produce highly effective inhibitors with unique mechanisms of action, ultimately striving to improve patient outcomes and transform lives.